Astellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below 50 Day Moving Average – Here’s What Happened

Astellas Pharma Inc. (OTCMKTS:ALPMY) crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $13.76 and traded as low as $13.1850. Astellas Pharma shares last traded at $13.25, with a volume of 134,199 shares traded.

Analyst Upgrades and Downgrades

ALPMY has been the topic of several analyst reports. Zacks Research upgraded Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 23rd. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Two investment analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Astellas Pharma Stock Up 0.5%

The company’s fifty day simple moving average is $13.76 and its 200-day simple moving average is $14.64. The firm has a market capitalization of $23.98 billion, a PE ratio of 12.34 and a beta of 0.07. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.09 and a quick ratio of 0.84.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Monday, April 27th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.19 by $0.14. The firm had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.28 billion. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%. On average, analysts forecast that Astellas Pharma Inc. will post 1.25 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).